118 related articles for article (PubMed ID: 26819537)
1. Treatment of chronic hepatitis B patients with tyrosine-methionine-aspartate-aspartate mutations.
Calica Utku A; Karabay O
World J Gastroenterol; 2016 Jan; 22(4):1727-8. PubMed ID: 26819537
[TBL] [Abstract][Full Text] [Related]
2. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.
Tan YW; Ye Y; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
World J Gastroenterol; 2015 Feb; 21(7):2089-95. PubMed ID: 25717242
[TBL] [Abstract][Full Text] [Related]
3. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.
Kim JW; Lee HS; Woo GH; Yoon JH; Jang JJ; Chi JG; Kim CY
Clin Infect Dis; 2001 Aug; 33(3):403-5. PubMed ID: 11438912
[TBL] [Abstract][Full Text] [Related]
4. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
5. Clinical potential of emerging new agents in hepatitis B.
Farrell GC
Drugs; 2000 Oct; 60(4):701-10. PubMed ID: 11085196
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.
Lee SH; Kim HS; Byun IS; Jeong SW; Kim SG; Jang JY; Kim YS; Kim BS
J Med Virol; 2012 Feb; 84(2):217-22. PubMed ID: 22170540
[TBL] [Abstract][Full Text] [Related]
7. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
Liaw YF
Antivir Chem Chemother; 2001; 12 Suppl 1():67-71. PubMed ID: 11594691
[TBL] [Abstract][Full Text] [Related]
8. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
Yeh CT; Chien RN; Chu CM; Liaw YF
Hepatology; 2000 Jun; 31(6):1318-26. PubMed ID: 10827158
[TBL] [Abstract][Full Text] [Related]
9. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients.
Seta T; Yokosuka O; Imazeki F; Tagawa M; Saisho H
J Med Virol; 2000 Jan; 60(1):8-16. PubMed ID: 10568756
[TBL] [Abstract][Full Text] [Related]
10. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
Arslan U; Ural O; Findik D
Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic efficacy of combined application of lamivudine and bushen recipe in treating chronic hepatitis B and its influence on YMDD motif].
Zhou F; Wang LT; Chen JJ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2003 Jun; 23(6):417-20. PubMed ID: 12872391
[TBL] [Abstract][Full Text] [Related]
12. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
13. YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study.
Tan YW; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
Braz J Infect Dis; 2012; 16(3):250-5. PubMed ID: 22729192
[TBL] [Abstract][Full Text] [Related]
14. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis.
Tan Y; Ding K; Su J; Trinh X; Peng Z; Gong Y; Chen L; Cui Q; Lei N; Chen X; Yu R
PLoS One; 2012; 7(3):e32789. PubMed ID: 22479339
[TBL] [Abstract][Full Text] [Related]
15. [A real-time PCR assay for the quantification of hepatitis B virus DNA and concurrent detection of YMDD motif mutations].
Ağca H; Sayıner AA; Sengönül A; Simşek I; Akarsu M
Mikrobiyol Bul; 2011 Oct; 45(4):664-76. PubMed ID: 22090297
[TBL] [Abstract][Full Text] [Related]
16. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
Liaw YF
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl 3():S333-7. PubMed ID: 12472959
[TBL] [Abstract][Full Text] [Related]
17. Prolonged persistence of lamivudine-resistant mutant and emergence of new lamivudine-resistant mutants two years after lamivudine withdrawal in HBsAg-positive chronic hepatitis patient: a case report.
Orlando R; Tosone G; Portella G; Veropalumbo E; D'Onofrio M; Piazza M
Infection; 2008 Oct; 36(5):472-4. PubMed ID: 17962902
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and virologic characteristics of lamivudine resistance in HBV-associated chronic liver disease].
Kim SS; Chung MG; Ju KT; Park DK; Kwon OS; Koo YS; Kim YK; Choi DJ; Hwang YJ; Kim JH
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):405-17. PubMed ID: 12506245
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
Papatheodoridis GV; Dimou E; Papadimitropoulos V
Am J Gastroenterol; 2002 Jul; 97(7):1618-28. PubMed ID: 12135009
[TBL] [Abstract][Full Text] [Related]
20. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.
Tipples GA; Ma MM; Fischer KP; Bain VG; Kneteman NM; Tyrrell DL
Hepatology; 1996 Sep; 24(3):714-7. PubMed ID: 8781348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
